Results 121 to 130 of about 23,653 (152)
Some of the next articles are maybe not open access.

Virologic Failure of High-Dose Raltegravir With Concomitant Rifampin

Infectious Diseases in Clinical Practice, 2017
Abstract Treating mycobacterial infections and HIV concurrently typically presents difficulties due to drug-to-drug interactions between rifampin and many antiretrovirals. We present a case of raltegravir failure during concomitant rifampin use, despite documented administration of recommended increased dose of raltegravir.
Misty M. Miller   +2 more
openaire   +1 more source

Low-level viremia linked to virological failure but not clinical events

AIDS
Introduction: The main objective of antiretroviral therapy (ART) for people with HIV (PWH) is to maintain an undetectable viral load. This study evaluates the association between low-level viremia (LLV) (50–200 copies/ml) and virological failure, AIDS, and severe non-AIDS events, as well as the impact of sociodemographic and ...
Bernal E   +15 more
openaire   +3 more sources

Management of patients with virologic and metabolic failure.

The AIDS reader, 2003
The greatest challenge faced by HIV-treating clinicians today is the management of virologic failure and metabolic complications of anti-HIV treatment. Resistance testing plays an essential role in selecting appropriate agents for salvage therapy. Too often, however, the choice of agents is limited by broad cross-resistance or toxicities, such as ...
openaire   +1 more source

Early virological failure with cabotegravir/rilpivirine

Journal of Antimicrobial Chemotherapy
L Bailón   +9 more
openaire   +5 more sources

Burden and Associated Factors of Virological Failure Among People Living with HIV in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

AIDS and Behavior, 2022
Chilot Desta Agegnehu   +2 more
exaly  

Characteristics of Patients on Antiretroviral Therapy With Prolonged Virological Failure

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
Sarita, Sharma   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy